A prospective multicenter validation of RETREAT for post-transplantation hepatocellular carcinoma recurrence prediction.

Background: The RETREAT score is a simple risk stratification tool for post-liver transplantation (LT) hepatocellular carcinoma (HCC) recurrence that has been validated in retrospective cohort studies. A prospective, multicenter study is needed to further demonstrate accuracy especially given evolving clinical demographics and HCC transplant practice.

Aim: To validate and compare the RETREAT score to other post-LT HCC recurrence risk scores in a contemporary, prospective cohort of patients.

Myotendinous Junction Anesthesia: An Alternative Infiltration Site for Ultrasound-Guided Injections.

The myotendinous junction is a highly specialized and complex structure between muscle and tendon. In recent years, various procedures have directly targeted the tendon, with corticosteroid, platelet-rich plasma, or biological therapy infiltrations being prominent. However, these interventions are painful, corticosteroids have demonstrated tendon damage, and anesthesia negatively impacts tenocyte proliferation and viability when used with platelet-rich plasma in the same injection site.

Provider use of a participatory decision-making style with youth with ADHD and their caregivers and visit satisfaction.

Objective: To examine whether youth with ADHD who received a question prompt list and video intervention and their caregivers were more likely to: (a) be asked about their treatment preferences, (b) have their input included into treatment decisions, (c) rate their providers as using more of a participatory decision-making (PDM) style, and (d) be more satisfied with their visits.

Methods: Youth with ADHD were randomized to a pre-visit question prompt list intervention or usual care. Visits were audio-recorded; youth were interviewed after visits; caregivers completed questionnaires.

Comprehensive analysis of relapsed-refractory mature B-cell non-Hodgkin lymphoma in children and adolescents.

The outcome of B-cell non-Hodgkin lymphoma (B-NHL) in children and adolescents has improved significantly over recent decades due to risk-adapted strategies and the use of immunotherapy. However, refractory or relapsed (R/R) B-NHL remains extremely difficult to cure (<30%). This retrospective study of 45 patients with R/R B-NHL reflects the limited benefit associated with reintroducing rituximab in second-line strategies, the importance of achieving complete remission before stem cell transplantation and the potential role of TP53 as a biomarker in R/R B-NHL.